Investigation Report on China’s Diclofenac Market, 2019-2023

$2,200$3,300

Clear
SKU: 1908401 Categories: , Tag:

Description

Description
Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.
Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.
Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.
Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.
Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI’s market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.
It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:
– Market size of Urokinase in China
– Competitive landscape of China’s Urokinase market
– Prices of Urokinase in China
– Favorable and unfavorable factors influencing China’s Urokinase market
– Prospect of China’s Urokinase market

Table of Contents

Table of Contents
1 Relevant Concepts of Diclofenac
1.1 Indications for Diclofenac
1.2 Development of Diclofenac in China
1.3 Patents and Government Approval on Diclofenac in China

2 Sales of Diclofenac in China, 2013-2017
2.1 Sales Value of Diclofenac
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Diclofenac
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Diclofenac by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules
2.3.3 Gels
2.3.4 Sprays
2.3.5 Suppositories
2.3.6 Injections
2.3.7 Eye Drops
2.3.8 Patches
2.3.9 Ointments (Creams)

3 Analysis on Major Diclofenac Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Diclofenac Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Beijing Novartis Pharma Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Diclofenac by Beijing Novartis Pharma Co., Ltd. in China
3.3 Shenyang Xingqi Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Diclofenac by Shenyang Xingqi Pharmaceutical Co., Ltd. in China
3.4 Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd.
3.5 KlingePharma
3.6 Fujisawa

4 Prices of Diclofenac in China, 2017-2018
4.1 Beijing Novartis Pharma Co., Ltd. (Voltaren)
4.2 Shenyang Xingqi Pharmaceutical Co., Ltd. (Difei)
4.3 Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. (Laibixin)
4.4 KlingePharma
4.5 Fujisawa (Difene)

5 Prospect of China’s Diclofenac Market, 2019-2023
5.1 Factors Influencing Development of China’s Diclofenac Market
5.1.1 Favorable Factors
5.1.2 Unfavorable Factors
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Patents on Diclofenac in China
Chart Government Approval on Diclofenac in China
Chart Sales of Diclofenac in China, 2013-2017
Chart Sales Value of Diclofenac in Parts of China, 2013-2017
Chart Sales Volume of Diclofenac in China, 2013-2017
Chart Sales Volume of Diclofenac in Parts of China, 2013-2017
Chart Sales Value of Diclofenac Tablets in China, 2013-2017
Chart Sales Volume of Diclofenac Tablets in China, 2013-2017
Chart Sales Value of Diclofenac Capsules in China, 2013-2017
Chart Sales Value of Diclofenac Gels in China, 2013-2017
Chart Sales Value of Diclofenac Sprays in China, 2013-2017
Chart Sales Value of Diclofenac Suppositories in China, 2013-2017
Chart Sales Value of Diclofenac Injections in China, 2013-2017
Chart Sales Value of Diclofenac Eye Drops in China, 2013-2017
Chart Sales Value of Diclofenac Patches in China, 2013-2017
Chart Sales Value of Diclofenac Ointments (Creams) in China, 2013-2017
Chart Market Share of Top 5 Diclofenac Manufacturers by Sales Value in China, 2013-2017
Chart Sales Value of Diclofenac by Beijing Novartis Pharma Co., Ltd. in China, 2013-2017
Chart Sales Value of Diclofenac by Shenyang Xingqi Pharmaceutical Co., Ltd. in China, 2013-2017
Chart Sales Value of Diclofenac by Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd.  in China, 2013-2017
Chart Sales Value of Diclofenac by KlingePharma in China, 2013-2017
Chart Sales Value of Diclofenac by Fujisawa in China, 2013-2017
Chart Prices of Diclofenac by Beijing Novartis Pharma Co., Ltd. in Parts of China, 2017
Chart Prices of Diclofenac by Shenyang Xingqi Pharmaceutical Co., Ltd.  in Parts of China, 2017
Chart Prices of Diclofenac by Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. in Parts of China, 2017
Chart Prices of Diclofenac by KlingePharma in Parts of China, 2017
Chart Prices of Diclofenac by Fujisawa in Parts of China, 2017
Chart Forecast on Sales Value of Diclofenac in China, 2019-2023

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format